Treatment Options for BCR After Local Therapy for Prostate Cancer
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
Clinical Pearls
Rana R. McKay, MD, a clinical oncology fellow at Dana-Farber Cancer Institute, discusses treatment options for biochemical relapse after definitive local therapy for prostate cancer.
- Biochemical relapse is a heterogenous disease state and is likely related to tumor biology
- Classically, patients who have received a radical prostatectomy may be candidates for salvage radiation therapy with or without hormone therapies
- Patients who initially received primary radiation therapy may be candidates for salvage radical prostatectomy or hormone therapy
- In a previous study, patients in this space were essentially cured following treatment with docetaxel plus estramustine and ADT
- This trial, presented at the 2014 Genitourinary Cancers Symposium, aimed to determine the benefit of docetaxel plus bevacizumab and ADT
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
